Cargando…

Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report

Real-life data on the performance of vaccines against SARS-CoV-2 are still limited. We here present the rates of detection and levels of antibodies specific for the SARS-CoV-2 spike protein RBD (receptor binding domain) elicited by four vaccines available in Serbia, including BNT-162b2 (BioNTech/Pfi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lijeskić, Olivera, Klun, Ivana, Stamenov Djaković, Marija, Gligorić, Nenad, Štajner, Tijana, Srbljanović, Jelena, Djurković-Djaković, Olgica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470459/ https://www.ncbi.nlm.nih.gov/pubmed/34579268 http://dx.doi.org/10.3390/vaccines9091031

Ejemplares similares

Toxoplasma gondii Genotypes Circulating in Serbia—Insight into the Population Structure and Diversity of the Species in Southeastern Europe, a Region of Intercontinental Strain Exchange
por: Uzelac, Aleksandra, et al.
Publicado: (2021)

Three Outbreaks of COVID-19 in a Single Nursing Home over Two Years of the SARS-CoV-2 Pandemic
por: Čokić, Vladan, et al.
Publicado: (2023)

Computational image analysis reveals the structural complexity of Toxoplasma gondii tissue cysts
por: Bauman, Neda, et al.
Publicado: (2020)

Prenatal and Early Postnatal Diagnosis of Congenital Toxoplasmosis in a Setting With No Systematic Screening in Pregnancy
por: Stajner, Tijana, et al.
Publicado: (2016)

Epidemiology of Toxoplasmosis in SERBIA: A Cross-Sectional Study on Blood Donors
por: Stopić, Milena, et al.
Publicado: (2022)

A Pork Industry in the Backyard: An Analysis of Toxoplasma gondii Infection in Serbia’s Pigs
por: Uzelac, Aleksandra, et al.
Publicado: (2023)

Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines
por: Kokić, Zoran, et al.
Publicado: (2023)

Seroprevalence, Direct Detection and Risk Factors for Toxoplasma gondii Infection in Pigs in Serbia, and Influence of Biosecurity Measures
por: Betić, Nikola, et al.
Publicado: (2022)

Toxoplasma gondii infection in slaughter pigs in Serbia: seroprevalence and demonstration of parasites in blood
por: Klun, Ivana, et al.
Publicado: (2011)

Human giardiasis in Serbia: asymptomatic vs symptomatic infection
por: Nikolić, A., et al.
Publicado: (2011)

In Vivo and In Vitro Virulence Analysis of Four Genetically Distinct Toxoplasma gondii Lineage III Isolates
por: Uzelac, Aleksandra, et al.
Publicado: (2020)

The Prognosis of Late Presenters in the Era of Highly Active Antiretroviral Therapy in Serbia
por: Jevtović, Djordje, et al.
Publicado: (2009)

The first isolation and molecular characterization of Toxoplasma gondii from horses in Serbia
por: Klun, Ivana, et al.
Publicado: (2017)

Antimalarials with Benzothiophene Moieties as Aminoquinoline Partners
por: Konstantinović, Jelena, et al.
Publicado: (2017)

SARS-CoV-2: To be or not to be vaccinated?
por: Beauchet, Olivier
Publicado: (2021)

The comparison of SARS-CoV-2 antibody levels in medical personnel induced by different types of vaccines compared to the natural infection
por: Božić, Ljiljana, et al.
Publicado: (2023)

The Coronaviruses of Animals and Birds: Their Zoonosis, Vaccines, and Models for SARS-CoV and SARS-CoV2
por: Alluwaimi, Ahmed M., et al.
Publicado: (2020)

Risk of appendicitis after SARS-CoV-2 infection and SARS-CoV-2 vaccination
por: Ljung, Rickard, et al.
Publicado: (2022)

Development of vaccines for SARS-CoV-2
por: Ng, Wern Hann, et al.
Publicado: (2020)

Inactivated vaccine for SARS-CoV-2
por: Risson, Emma
Publicado: (2020)

Nanocarrier vaccines for SARS-CoV-2
por: Machhi, Jatin, et al.
Publicado: (2021)

SARS-CoV-2 Vaccines and the Skin()
por: Galván-Casas, C., et al.
Publicado: (2021)

SARS CoV2 vaccine and aphasia
por: sookaromdee, Pathum, et al.
Publicado: (2021)

SARS-CoV-2 Variants and Vaccines
por: Krause, Philip R., et al.
Publicado: (2021)

SARS-CoV-2 vaccine development
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Esophagitis and SARS-CoV-2 vaccine
por: Sriwijitalai, Won, et al.
Publicado: (2023)

SARS-CoV-2 vaccination in pregnancy
por: Dalcin, Daniel, et al.
Publicado: (2023)

The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
por: Molaei, Soheila, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors
por: Duan, Li-Jun, et al.
Publicado: (2022)

Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines
por: Yue, Can, et al.
Publicado: (2023)

Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV
por: Xie, Mingxuan, et al.
Publicado: (2020)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China
por: Zhang, Xi-Ru, et al.
Publicado: (2023)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
por: Liu, William J., et al.
Publicado: (2017)

Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers
por: Cucunawangsih, Cucunawangsih, et al.
Publicado: (2021)

Animal models and vaccines for SARS-CoV infection
por: Roberts, Anjeanette, et al.
Publicado: (2008)

In Pursuit of a SARS-CoV-2 Vaccine
por: Johnson, Alton R., et al.
Publicado: (2020)

SARS-CoV2 vaccines: Slow is fast
por: Green, Douglas R.
Publicado: (2020)

SARS-CoV-2 Vaccines: Status Report
por: Amanat, Fatima, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ur55rgg011uotun5144e2u5qar